[Federal Register Volume 64, Number 27 (Wednesday, February 10, 1999)]
[Notices]
[Pages 6668-6669]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-3238]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Method Of Using A 2-Adrenergic Receptor
Agonist That Selectively Activates Gs Proteins In The
Treatment Of Cardiovascular Disease
Rui-Ping Xiao, Edward G Lakatta, Heping Cheng (NIA)
Serial No. 60/102,475 filed 30 Sep 98
Licensing Contact: Charles Maynard; 301/406-7735 ext. 243;
e-mail: cm251n@nih.gov
This technology relates to a method of using 2-
adrenergic receptor agonist that selectively activates Gs
proteins in the treatment of cardiovascular disease. In particular,
this invention relates to a method of using fenoterol to activate
selectively Gs proteins in the treatment of acute heart
failure, chronic heart failure and aging heart. In the heart,
-adrenergic receptor (AR) stimulation provides the
primary regulatory mechanism on cardiac function. There are at least
two AR subtypes, namely 1AR and
2AR, that exist in the myocardium, although
1AR predominates. While 1AR
couples to stimulatory G proteins (Gs),
2AR elicits bifurcated signaling pathways mediated
by Gs and Gi, resulting in functionally opposing
effects on cardiac function. In failing and aged hearts, the overall
response to AR stimulation is markedly diminished due to the
down-regulation of 1AR and an up-regulation of
Gi proteins.
This invention is predicated on the surprising and unexpected
discovery that a 2AR agonist can selectively
activate Gs proteins, and is further predicated on the
discovery that selective activation of Gs proteins by a
2AR agonist can revive AR contractile
support in failing hearts.
An object of the present invention is to provide ligands (agonists
and antagonists), and methods for the selective activation and
inactivation of a subset of signaling pathways coupled to any given
receptor of any cell or tissue type. It is another object of the
present invention to provide ligands and methods for the selective
activation and inactivation of a subset of signaling pathways involving
G proteins. In particular, Gs and Gi proteins
coupled to a cardiovascular receptor such as 2 AR
for the treatment of cardiovascular disease.
Aminohydroxylated Adenine Derivatives
KB Sharpless, DM Jerina, KR Dress, LJ Goossen, AS Pilcher, H Kroth,
AR Ramesha (NIDDK)
Serial No. 60/091,900 filed 07 Jul 98
Licensing Contact: Charles Maynard; 301/496-7735 ext. 243; e-mail:
cm251n@nih.gov
The invention herein describes a process for the addition of
adenine and its derivatives to olefins to produce cis-vicinal
aminoalcohols. The adenine moiety is contained in numerous drugs as
well as plant growth regulators. In addition, adducts of purine bases
in
[[Page 6669]]
DNA have been implicated in the transformation of normal cells to tumor
cells. A key feature of the synthesis is that it provides a one-step
high yield process for the production of adducts derived from the cis-
opening of diol epoxide metabolites from polycyclic aromatic
hydrocarbons. Previously such cis-opened adducts have not been readily
accessible.
This technology provides compositions and synthetic methods for the
preparation of important biologically active compounds. Typically,
admixing adenine, olefin and ligand in the absence of oxygen with an
appropriate catalyst produces the desired product for a wide range of
substituted olefins and amino derivatives.
Mammalian Gene Insertion Libraries
X Zheng, CL Steward, SH Hughes, EV Barsov (NCI)
Serial No. 09/069,127 filed 28 Apr 98
Licensing Contact: Richard Rodriguez; 301/496-7056 ext. 287; e-mail;
rr154z@nih.gov
Sequencing of the genomes of higher organisms is progressing
rapidly, but only a fraction of the open reading frames and cDNAs whose
sequence are known have functions associated with them. There is
therefore a great need to assign functions to these open reading
frames. One method of achieving this goal is insertional mutagenesis
using transposable elements. An insertion into a gene not only alters
the structure of the gene but also serves as a molecular marker for
characterizing and cloning the targeted gene. While effective, this
approach has been problematic in mammals due to the large size and
complexity of mammalian genomes and the lack of appropriate mammalian
transposable elements. The current invention provides a mammalian
insertional mutation library in which each cell has one or more copies
of a vector inserted into its genome at essentially random locations,
and the library as a whole includes insertions in the majority of the
genes of the genome. The cells used to create the libraries can be of a
variety of types, including totipotent cells, and can be used to
generate a whole animal. The unique vectors used to make the libraries
are retrovirus-based, replication-deficient in mammalian cells and are
efficiently produced in avian cells at high titers. This technology
allows for the efficient creation of transgenic mice in which a
detailed investigation of the cellular processes that are affected by
the expression of mutated gene sequences can be performed as well as an
analysis of the consequences on the physiology of the whole animal.
Preparation of Chiral 5-Aminocarbonyl-5H-Dibenzo[A,D]Cyclohepten-
5,10-Imines by Optical Resolution
TH Jones, Kc Rice (NIDDK)
Serial No. 08/420,013 filed 11 Apr 95; U.S. Patent No. 5,686,414 issued
11 Nov 97
Licensing Contact: Leopold Luberecki, Jr.; 301/496-7735 ext. 223; e-
mail: 1187a@nih.gov.
This case discloses a means for chiral separation of 5-
Aminocarbonyl-5H-Dibenz0[A,D] Cyclohepten-5,10-Imines (ADCI), a
compound under development by an exclusive licensee as a treatment for
epilepsy and nervous system disorders. Approximately one percent of the
American population suffers from epilepsy or related seizure disorders,
and many of these patients do not respond to currently available
antiseizure medications. It can be assumed that if one of the
enantiomeric forms of ADCI is more active than the other, the U.S. Food
and Drug Administration and its equivalent foreign counterparts will
require use of that stereoisomeric form of the compound.
A Novel Mouse Model For Non-Insulin Dependent (TYPE II) Diabetes
Mellitus
CR Kahn, JC Bruening, D Accili (NICHD)
DHHS Reference No. E-123-96/0 filed 07 Jun 96
Licensing Contact: Charles Maynard; 301/496-7735 ext. 243;
e-mail: cm251n@nih.gov.
This technology relates to animal models of polygenic insulin-
related disorders and methods of using such animals. The invention
features a ``genetically engineered'' non-human animal having a first
and second mutation in genes important for insulin action. The double
``knockout'' animal is useful as a model of polygenic insulin-related
disorders, e.g., type II diabetes. Non-insulin dependent (TYPE II)
diabetes mellitus (NIDDM) is among the most common of all metabolic
disorders, affecting 6-7% of the U.S. population. Currently no good
animal models exist for NIDDM. The most frequently used models are
models of genetic obesity. In these obesity models, there is gradual
development of insulin resistance as the obesity increases. The Goto-
Kitazak (GK) rat has been proposed as a non-obese model of NIDDM,
although the diabetes in this case is quite mild and the pathogenesis
is much less well understood. Thus, a need still exists to develop a
novel mouse model that closely resembles human NIDDM disease.
Dated: February 1, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 99-3238 Filed 2-9-99; 8:45 am]
BILLING CODE 4140-01-M
